Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Secukinumab · Cosentyx, AIN-457

Monoclonal antibody · Antagonist of interleukin-17A (IL17A) · developed by Novartis Pharms

Approved FDA, Jan 2015
NVS Developer
1 Registered trials

What is Secukinumab?

Secukinumab is a human IgG1 monoclonal antibody that binds the pro-inflammatory cytokine interleukin-17A and blocks its interaction with the IL-17 receptor, reducing inflammatory signaling. It is studied in psoriasis and related immune-mediated inflammatory diseases.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Cosentyx, AIN-457, AIN457A, Secikinumab
Drug type
Monoclonal antibody
Targets
interleukin-17A (IL17A)
Mechanism
Antagonist of interleukin-17A (IL17A)
Pathways
IL-17A/IL-17R signaling, release of proinflammatory cytokines and chemokines
Therapy area
Dermatology
Developer
Novartis Pharms Corp (NVS)
FDA status
Approved as Cosentyx (January 21, 2015), BLA125504 · FDA label
UNII
DLG4EML025

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 25, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02786186 N/A Psoriasis Completed NVS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Psoriasis

Other drugs acting on IL17A

More from Novartis Pharms

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the NVS page.

Follow NVS, the company behind Secukinumab

See NVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NVS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.